* TELA Bio Inc is expected to show a rise in quarterly revenue when it reports results on November 7 for the period ending January 1 0001

* The Malvern Pennsylvania-based company is expected to report a 25.2% increase in revenue to $18.852 million from $15.05 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for TELA Bio Inc is for a loss of 40 cents per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts was unchanged in the last three months. ​

* Wall Street's median 12-month price target for TELA Bio Inc is 12.00​, above​ its last closing price of $2.92. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Jun. 30 2024 -0.46 -0.47 -0.51 Missed -8.1

Jan. 1 2024 -0.51 -0.50 -0.23 Beat 54.1

Jan. 1 0001 -0.42 -0.43 -0.53 Missed -21.9​

Jan. 1 0001 -0.49 -0.49 -0.45 Beat 8.5

​​Jan. -0.53 -0.53 -0.46 Beat 13.7

1 0001

Jan. 1 0001 -0.56 -0.56 -0.63 Missed -12.7​

Dec. 31 2022 -0.51 -0.55 -0.52 Beat 4.8

Sep. 30 2022 -0.63 -0.63 -0.64 Missed -2.3

This summary was machine generated November 6 at 04:35 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)